Mariana Cabral*, Direndra Hasmucrai, Filipa Ferro, Ana Sofia Vilariça and Paula Alves
Santa Marta Hospital - Central Lisbon Hospital and University Center, PortugalFulltext PDF
Pulmonary carcinoids are relatively rare neuroendocrine neoplasms, accounting for only 1% to 2% of malignant thoracic tumors.
Retrospective analysis of all cases of lung carcinoid tumors followed at a Portuguese hospital from 01/2017 to 12/2021.
Fifty-one patients were included, predominantly female and non-smokers; the mean age was 60.3 years. Nearly 40% underwent somatostatin receptor-based imaging; those who did 68Ga-DOTANOC PET, 82% were positive; those who underwent OCTREOSCAN, 40% were positive.
The final diagnosis was Typical Carcinoid (TC) in 55% and Atypical Carcinoid (AC) in 41%; in 4% it was not possible to make a histological differentiation. Stage I was the most frequent (61%), followed by stage IV (18%) in which the majority (67%) was represented by atypical carcinoid. The most common metastasis site was the lung, followed by bone and liver. Regarding treatment, ¾ of the patients went through surgery, of which two also did adjuvant Chemotherapy (CT); two underwent
endoscopic treatment. In the advanced stage, one patient was under 1st line CT (cisplatin+etoposide) and two were under 3rd line (carboplatin+etoposide), after other lines of treatment with everolimus, octreotide and CT. Two patients, positive for somatostatin receptor, were treated with octreotide, and in 3 patients the chosen attitude was surveillance. There were two deaths, but none of them related to the neoplastic disease.
Well-differentiated neuroendocrine lung tumors differ substantially from other lung neoplasms. Most of them are diagnosed in early stages and the treatment is essentially based on surgical resection, with good prognosis.
Cabral M, Hasmucrai D, Ferro F, Sofia Vilariça A, Alves P. Lung Carcinoids - 5 Years Analysis in a Tertiary Hospital. Clin Oncol. 2022;7:1920..